AbbVie Inc. Q1 2026 results

These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. We are delivering top-tier growth and continue to strengthen our long-term outlook with pipeline advancements and strategic transactions. Turning to our first quarter performance, we achieved adjusted earnings per share of $2.65, which is $0.07 above our guidance midpoint. Total net revenues were $15 billion, beating our expectations by $300 million and reflecting robust sales growth of 12.4%.

Based on this strong performance, we are raising our full year adjusted earnings per share guidance by $0.12 and now expect adjusted EPS between $14.08 and $14.28. regulatory submissions of RINVOQ for alopecia areata, giving us a potential new source of growth in dermatology, and SKYRIZI sub-Q induction in Crohn's, with an approval decision expected later this year. We also expanded our emerging oncology pipeline by closing the RemeGen agreement, giving us a novel PD-1/VEGF bispecific antibody. Given our strong growth outlook, we have significant financial capacity to pursue both early and late-stage opportunities.

R&D and capital investments over the next decade, we recently announced construction of several new manufacturing sites. In summary, the fundamentals of our business are strong, and we are well-positioned to deliver top-tier growth for the long term. I'll start with the quarterly results for immunology, which delivered total revenues of $7.3 billion, reflecting impressive sales growth of $1 billion. We continue to demonstrate exceptional performance across psoriatic disease, where we are gaining share and have clear leadership over all biologics and orals by a very wide margin.